Cell death inhibitor

a cell death inhibitor and inhibitor technology, applied in the field of cell death inhibitors, can solve the problems of no report on the mechanism of cell death, the relationship between mif and cell death is unknown, etc., and achieve the effects of preventing myocardial cell death, preventing serum depletion-induced cell death, and increasing gene expression

Inactive Publication Date: 2006-02-16
TAKEDA PHARMA CO LTD
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] In view of the foregoing situations, the present inventors have made extensive studies and as a result, found that monoclonal antibodies against macrophage migration inhibitory factors (MIF), low molecular compounds capable of binding to MIF and the like prevent serum depletion-induced cell death in rat primary cardiomyocytes. Furthermore, the inventors have found that low molecular compounds capabl

Problems solved by technology

However, the relationship between MIF and cell death is unknown except for the mouse B cell

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cell death inhibitor
  • Cell death inhibitor
  • Cell death inhibitor

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

2-(2-Pyridyl)-4H-1,3-benzothiazin-4-one (Compound 1)

[0122]

[0123] Methyl thiosalicylate (1.6 g, 9.51 mM) and 2-cyanopyridine (1.0 g, 9.60 mM) were dissolved in toluene (2 ml), and triethylamine (2 ml, 14.4 mM) was added to the solution. After heating for 8 hours under reflux, toluene was removed by distillation. Ethanol was added to the residue and the precipitates were taken out by filtration to give crude crystals (1.7 g). The crude crystals were purified by silica gel column chromatography (hexane: chloroform=5:1→chloroform) to give the title compound as crystals (1.0 g, 43.4%).

[0124] Elemental analysis as C13H8N2OS

[0125] Calcd. (%) C, 64.98; H, 3.36, N, 11.66.

[0126] Found (%) C, 64.93; H, 3.31, N, 11.59.

[0127]1H-NMR (CDCl3) δ: 7.50-7.75 (m,4H), 7.85-8.00 (m,1H), 8.50-8.60 (m,2H), 8.70-8.80 (m,1H).

[0128] IR (KBr): 1660 cm−1

reference example 2

2-(3-Pyridyl)-4H-1,3-benzothiazin-4-one

[0129]

[0130] Methyl thiosalicylate (1.8 g, 10.7 mM) and 3-cyanopyridine (1.1 g, 10.56 mM) were dissolved in toluene (5 ml), and triethylamine (2 ml, 14.4 mM) was added to the solution. After heating for 48 hours under reflux, the same procedures as in REFERENCE EXAMPLE 1 were carried out to give the title compound as crystals (1.1 g, 43.4%).

[0131] Elemental analysis as C13H8N2OS

[0132] Calcd. (%) C, 64.98; H, 3.36, N, 11.66.

[0133] Found (%) C, 64.97; H, 3.33, N, 11.63.

reference example 3

2-(4-Pyridyl)-4H-1,3-benzothiazin-4-one

[0134]

[0135] Methyl thiosalicylate (2.0 g, 11.9 mM) and 4-cyanopyridine (1.2 g, 11.5 mM) were dissolved in toluene (5 ml), and triethylamine (2 ml) was added to the solution. After heating for 22 hours under reflux, the same procedures as in REFERENCE EXAMPLE 1 were carried out to give the title compound as crystals (850 mg, 30.7%).

[0136] Elemental analysis as C13H8N2OS

[0137] Calcd. (%) C, 64.98; H, 3.36, N, 11.66.

[0138] Found (%) C, 65.07; H, 3.15, N, 11.62.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Antioxidantaaaaaaaaaa
Inhibitionaaaaaaaaaa
Login to view more

Abstract

The cell death inhibitor comprising a substance capable of binding to macrophage migration inhibitory factor is useful as a preventive/therapeutic agent for, e.g., heart diseases, neurodegenerative diseases, cerebrovascular diseases, central nervous infections, traumatic diseases, demyelinating diseases, bone/joint diseases, kidney diseases, liver diseases, myelodysplastic diseases, arteriosclerosis, diabetes, pulmonary hypertension, sepsis, inflammatory bowel diseases, autoimmune diseases, failure accompanying rejection in organ transplantation, AIDS, cancer, etc.

Description

TECHNICAL FIELD [0001] The present invention relates to a cell death inhibitor, screening for the cell death inhibitor, and the like. BACKGROUND ART [0002] From the nature of processes to death, cell death is categorized into two types, necrosis and apoptosis. Necrosis is accidental cell death that accidentally occurs due to physical / chemical factors, etc. In contrast, apoptosis is cell death deeply involved in morphogenesis during the developmental process, tissue formation, maintenance of homeostasis, biological defense, etc. to play a critical role in supporting the individual's life, and the process is regulated by a gene. Congenital or acquired disorders of these cell death processes excessively induce or prevent cell death to cause dysfunctions of various organs, leading to diseases (SAISHIN-IGAKU, 54, 825, 1999). [0003] In recent years, it has been revealed that these types of cell death are deeply committed to the development or progress of various diseases (R. Sanders Willi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395A61K31/5415A61K31/00A61P43/00C07D279/08C07D417/04
CPCA61K31/00A61K31/5415G01N2500/02C07D417/04G01N2333/52C07D279/08A61P1/00A61P1/16A61P3/10A61P9/00A61P9/04A61P9/10A61P9/12A61P11/00A61P13/12A61P19/02A61P25/28A61P31/00A61P35/00A61P37/06A61P43/00
Inventor KIMURA, HARUHIDESATO, YOSHIMITAKIZAWA, MASAYUKIHORIGUCHI, TAKASHINOTOYA, KOHEI
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap